Solifenacin
From Pharmacopedia
More actions
Solifenacin
Vesicare
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Overactive bladder (urgency, frequency, urge incontinence)0, Neurogenic detrusor overactivity0
Pharmacy
Starting dose
5 mg PO once daily; titrate to 10 mg after 2 weeks if needed
Preparations
5, 10 mg tablets
US FDA Max
10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors)
Pharmacology
Routes
Oral
Onset
Symptom improvement within 1-2 weeks
Duration
24 hours
Half-life
~45-68 hours[1]
Bioavailability
~90% (oral)[1]
Pregnancy
Limited data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Solifenacin is a competitive muscarinic receptor antagonist with substantially higher selectivity for M3 (bladder detrusor) over M2 (cardiac) and M1 (CNS) than oxybutynin; the relative subtype selectivity reduces (but does not eliminate) the systemic anticholinergic burden.0 CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Vesicare (solifenacin succinate), Astellas, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021518s019lbl.pdf